Composite Cardiovascular outcomes (Figure 3)
The cardiovascular composite outcomes included cardiovascular-related
mortality, hospitalization for heart failure, nonfatal myocardial
infarction, and nonfatal stroke. All five studies[5,10,14-16] reported death from cardiovascular
causes and hospitalization due to heart failure, and the pooled analysis
revealed that treatment with Finerenone was associated with a
significantly decreased risk of death and hospitalization (RR = 0.86
[0.80, 0.93] p=0.0002; I2= 0%), (RR = 0.77 [0.70, 0.84] p
0.00001; I2= 0%), respectively. Non-fatal myocardial infarction and
non-fatal stroke were reported in four of the five studies[5,10,14,15], and the pooled analysis revealed
that treatment with Finerenone was associated with a decreased risk of
non-fatal myocardial infarction (RR = 0.89 [0.78, 1.02] p=0.09; I2=
0%) but there was no difference in risk of non-fatal stroke between the
two treatment groups (RR = 1.01 [0.89, 1.14] p=0.93; I2= 0%)